Trial Profile
Randomized phase III trial comparing adjuvant S-1 to capecitabine in stage III colorectal cancer (JCOG0910, CRC Adj-CAPS)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Sep 2022
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Capecitabine
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- 30 Aug 2022 Status changed from active, no longer recruiting to completed.
- 21 Sep 2020 Interim Results (n=1564) assessing six-year updated data of Japan Clinical Oncology Group study presented at the 45th European Society for Medical Oncology Congress
- 04 Jun 2019 Results analysing mutaion frequencies (n=534) presented at the 55th Annual Meeting of the American Society of Clinical Oncology.